1. Home
  2. WBX vs MNOV Comparison

WBX vs MNOV Comparison

Compare WBX & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

N/A

Current Price

$3.12

Market Cap

65.2M

ML Signal

N/A

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$3.29

Market Cap

70.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WBX
MNOV
Founded
2015
2000
Country
Spain
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.2M
70.4M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
WBX
MNOV
Price
$3.12
$3.29
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$4.75
$7.50
AVG Volume (30 Days)
10.2K
434.2K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,360,807.00
Revenue This Year
$18.10
N/A
Revenue Next Year
$94.11
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$2.30
$1.17
52 Week High
$7.83
$3.90

Technical Indicators

Market Signals
Indicator
WBX
MNOV
Relative Strength Index (RSI) 45.72 94.58
Support Level $2.77 $1.28
Resistance Level $3.19 N/A
Average True Range (ATR) 0.18 0.23
MACD 0.01 0.20
Stochastic Oscillator 19.87 86.50

Price Performance

Historical Comparison
WBX
MNOV

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: